Compare RYAM & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYAM | EOLS |
|---|---|---|
| Founded | 1926 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 422.1M | 444.0M |
| IPO Year | N/A | 2018 |
| Metric | RYAM | EOLS |
|---|---|---|
| Price | $5.84 | $6.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $6.00 | ★ $20.50 |
| AVG Volume (30 Days) | 544.0K | ★ 854.3K |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,471,356,000.00 | $285,823,000.00 |
| Revenue This Year | N/A | $14.24 |
| Revenue Next Year | $6.99 | $21.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 15.10 |
| 52 Week Low | $3.35 | $5.71 |
| 52 Week High | $8.56 | $17.12 |
| Indicator | RYAM | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 41.16 | 47.29 |
| Support Level | $5.59 | $7.01 |
| Resistance Level | $5.92 | $7.25 |
| Average True Range (ATR) | 0.22 | 0.24 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 27.93 | 18.49 |
Rayonier Advanced Materials Inc is engaged in the production of cellulose specialties, a natural polymer used in the manufacturing of various specialty chemical products, including liquid crystal displays, filters, textiles and performance additives for pharmaceutical, food and other industrial applications. The company's products are used in a variety of applications, including cigarette filters, liquid crystal displays, paints, pharmaceuticals, and food. The company operates in the reportable segments of High Purity Cellulose, Paperboard, and High-Yield Pulp. The key revenue is derived from the High Purity Cellulose segment. Geographically, it derives a majority of its revenue from the United States.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.